Redefining drug discovery for neuroscience R&D
Redefining drug discovery for neuroscience R&D
Key Papers
Drug connectivity mapping and functional analysis reveal therapeutic small molecules that
differentially modulate myelination
Functional genomic analyses highlight a shift in Gpr17-regulated cellular processes in oligodendrocyte progenitor cells and underlying myelin dysregulation in the aged mouse cerebrum
Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer's disease
Astrocytes are direct cellular targets of lithium treatment
Novel roles for lysyl oxidase and peroxisome-proliferator activated receptor-γ as astroglial targets of lithium: This study identified the mechanisms by which lithium regulates astrocye physiology and their relationship to major depressive disorders. The study further revealed and validated novel therapies for the treatment of bipolar disorder.
.jpg)
Pharmacogenomic identification of small molecules for lineage specific manipulation of
subventricular zone germinal activity
We established an entirely novel computational-based drug-discovery strategy to identify of small molecules that can be used to manipulate neural stem cells in different context. We provide proof that, by administration of small molecules in vivo, it is possible to promote the specific generation of neural cells in aging and regenerative contexts.